OR WAIT 15 SECS
After the acquisition of Genentech by Roche last month, the integration of the two companies has begun with the announcement of some changes to the organizational structure and key management positions.
After the acquisition of Genentech by Roche last month, the integration of the two companies has begun with the announcement of some changes to the organizational structure and key management positions, which will become effective 1 May 2009.
Arthur Levinson, currently Genentech chairman and CEO, will chair Genentech's new Board of Directors and steer the integration of Genentech and Roche on a strategic level. The board will include Roche executives as well as external members. He will also serve as an advisor to Genentech's Research and Early Development centre, which will operate as an independent centre within the Roche Group. Richard Scheller, currently EVP Genentech Research, will lead this centre and report directly to the Group's CEO Severin Schwan. Pascal Soriot will be appointed as CEO Genentech, which will combine Roche Pharma North America and Genentech.
"Roche and Genentech have always shared a focus on scientific discovery and a commitment to achieving medical breakthroughs that can enhance and even save lives," said Arthur Levinson. "The companies' efficient and strategic integration of its personnel and operations reflects these shared values, and I am confident that our combined organization will be even more capable of delivering significant achievements."
Additional information is available on-line at www.roche.com